27 research outputs found
The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographicaly diverse populations
Recently, a 6-kb duplication of exon 13, which creates a frameshift in the coding sequence of the BRCA1 gene, has been described in three unrelated U.S. families of European ancestry and in one Portuguese family. Here, our goal was to estimate the frequency and geographic diversity of carriers of this duplication. To do this, a collaborative screening study was set up that involved 39 institutions from 19 countries and included 3,580 unrelated individuals with a family history of the disease and 934 early-onset breast and/or ovarian cancer cases. A total of 11 additional families carrying this mutation were identified in Australia (1), Belgium (1), Canada (1), Great Britain (6), and the United States (2). Haplotyping showed that they are likely to derive from a common ancestor, possibly of northern British origin. Our results demonstrate that it is strongly advisable, for laboratories carrying out screening either in English-speaking countries or in countries with historical links with Britain, to include within their BRCA1 screening protocols the polymerase chain reaction-based assay described in this report
Re: Pretest Prediction of BRCA1 or BRCA2 Mutation by Risk Counselors and the Computer Model BRCAPRO
Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer.
Contains fulltext :
89389.pdf (publisher's version ) (Open Access
Contribution of <i>BRCAI</i> and <i>BRCA2</i> germ-line mutations to the incidence of breast cancer in young women: Results from a prospective population-based study in France
Contribution of <i>BRCAI</i> and <i>BRCA2</i> germ-line mutations to the incidence of breast cancer in young women: Results from a prospective population-based study in France
Genetic evidence and integration of various data sources for classifying uncertain variants into a single model.
Item does not contain fulltextGenetic testing often results in the finding of a variant whose clinical significance is unknown. A number of different approaches have been employed in the attempt to classify such variants. For some variants, case-control, segregation, family history, or other statistical studies can provide strong evidence of direct association with cancer risk. For most variants, other evidence is available that relates to properties of the protein or gene sequence. In this work we propose a Bayesian method for assessing the likelihood that a variant is pathogenic. We discuss the assessment of prior probability, and how to combine the various sources of data into a statistically valid integrated assessment with a posterior probability of pathogenicity. In particular, we propose the use of a two-component mixture model to integrate these various sources of data and to estimate the parameters related to sensitivity and specificity of specific kinds of evidence. Further, we discuss some of the issues involved in this process and the assumptions that underpin many of the methods used in the evaluation process